Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

34.29 +0.57 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 894,362
Open 33.54
Bid (Size) 33.48 (1)
Ask (Size) 35.98 (1)
Prev. Close 33.72
Today's Range 33.32 - 34.36
52wk Range 31.46 - 48.82
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
 
Via Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily

Performance

YTD
-8.75%
-8.75%
1 Month
-5.30%
-5.30%
3 Month
-7.72%
-7.72%
6 Month
-18.88%
-18.88%
1 Year
-4.43%
-4.43%

More News

Read More
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
Via Benzinga
Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
Via Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via Globe NewsWire
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
4 Analysts Have This to Say About Ionis Pharmaceuticals
Via Benzinga
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via Globe NewsWire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday
Via Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Via Investor's Business Daily
3 Biotech Stocks to Sell in October
Via InvestorPlace
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Via Investor's Business Daily
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Via Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Via Benzinga
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.